SOP for blinded trial management – Clinical Research Made Simple

SOP for Database Lock and Unblinding Control

digi — Tue, 02 Sep 2025 07:07:11 +0000

SOP for Database Lock and Unblinding Control

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Database-Lock-and-Unblinding-Control”
},
“headline”: “SOP for Database Lock and Unblinding Control in Clinical Trials”,
“description”: “This SOP establishes procedures for database lock and unblinding control in clinical trials, ensuring data integrity, blinded trial conduct, and compliance with ICH GCP, FDA, EMA, CDSCO, and WHO regulations.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Database Lock and Unblinding Control

Department	Clinical Research
SOP No.	CR/DATA/054/2025
Supersedes	NA
Page No.	1 of 22
Issue Date	26/08/2025
Effective Date	01/09/2025
Review Date	01/09/2026

Purpose

The purpose of this SOP is to define the process for locking clinical trial databases and managing unblinding in blinded trials. These procedures ensure the integrity of data, protect trial blinding, and guarantee regulatory compliance prior to statistical analysis and reporting.

Scope

This SOP applies to sponsors, data managers, statisticians, CROs, and investigators involved in database management. It covers final data cleaning, query resolution, SAE reconciliation, database lock procedures, and controlled unblinding.

Responsibilities

Data Manager: Ensures database is clean, all queries are resolved, and final dataset is ready for lock.
Statistician: Confirms database readiness for analysis and manages controlled unblinding procedures.
PI and Site Staff: Ensure source documents and CRFs are complete and verified before lock.
Sponsor/CRO: Approves database lock and oversees unblinding procedures.
QA Officer: Reviews database lock and unblinding records during audits and inspections.

Accountability

The sponsor is accountable for final database lock and controlled unblinding, while the data manager is responsible for operational execution and documentation.

Procedure

1. Pre-Lock Activities
Resolve all outstanding data queries.
Reconcile SAE data with safety database.
Perform consistency checks and final data cleaning.
Conduct a pre-lock review meeting (data management, biostatistics, QA, sponsor).

2. Database Lock
Once all discrepancies are resolved, lock the database in the validated clinical data management system (CDMS).
Generate final data listings and archive them in TMF.
Record lock details in Database Lock Log (Annexure-1).

3. Unblinding Control
Controlled unblinding may only occur after sponsor authorization.
Emergency unblinding (subject-specific) is permitted only for safety reasons and must be documented in Emergency Unblinding Log (Annexure-2).
For interim analyses, partial unblinding must follow pre-defined statistical analysis plan (SAP).

4. Documentation
File database lock certificates, meeting minutes, and logs in TMF.
Ensure ISF has subject-level unblinding documentation if applicable.

5. Archiving
Archive final locked database and unblinding records for at least 15 years or as per local regulations.

Abbreviations

SOP: Standard Operating Procedure
CRF: Case Report Form
PI: Principal Investigator
CRO: Clinical Research Organization
QA: Quality Assurance
TMF: Trial Master File
ISF: Investigator Site File
SAE: Serious Adverse Event
CDMS: Clinical Data Management System
SAP: Statistical Analysis Plan

Documents

Database Lock Log (Annexure-1)
Emergency Unblinding Log (Annexure-2)
Database Lock Certificate (Annexure-3)

References

Version: 1.0

Approval Section

Prepared By	Rajesh Kumar, Data Manager
Checked By	Sunita Reddy, QA Officer
Approved By	Dr. Anil Sharma, Principal Investigator

Annexures

Annexure-1: Database Lock Log

Date	Database Locked By	System	Remarks
12/09/2025	Rajesh Kumar	Medidata Rave	Final lock approved by sponsor

Annexure-2: Emergency Unblinding Log

Date	Subject ID	Reason for Unblinding	Authorized By	Outcome
15/09/2025	CT2025-SITE01-181	Severe adverse reaction requiring treatment adjustment	PI	Unblinded for safety

Annexure-3: Database Lock Certificate

Date	Database	Version	Locked By	Approved By
12/09/2025	Phase III Oncology Trial Database	v3.2	Data Manager	Sponsor

Revision History

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
26/08/2025	00	Initial version	New SOP creation	Head, Clinical Research

For more SOPs visit: Pharma SOP

SOP for Randomization and Blinding/Unblinding

digi — Sat, 23 Aug 2025 14:47:34 +0000

SOP for Randomization and Blinding/Unblinding

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Randomization-and-Blinding-Unblinding”
},
“headline”: “SOP for Randomization and Blinding/Unblinding in Clinical Trials”,
“description”: “This SOP establishes procedures for randomization, blinding, and unblinding in clinical trials to ensure trial integrity, unbiased results, and compliance with ICH GCP, FDA, EMA, CDSCO, and WHO standards.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Randomization and Blinding/Unblinding

Department	Clinical Research
SOP No.	CR/IP/036/2025
Supersedes	NA
Page No.	1 of 22
Issue Date	26/08/2025
Effective Date	01/09/2025
Review Date	01/09/2026

Purpose

The purpose of this SOP is to describe standardized procedures for randomization, blinding, and unblinding in clinical trials. These processes ensure unbiased allocation of investigational products, maintain trial integrity, and safeguard subject safety.

Scope

This SOP applies to all clinical trial staff involved in randomization, blinding, and unblinding, including investigators, pharmacists, data managers, CROs, and sponsors. It covers randomization via IVRS/IWRS systems, manual methods, maintenance of blind, and emergency unblinding procedures.

Responsibilities

Principal Investigator (PI): Oversees randomization and ensures blinding is maintained throughout the trial.
Pharmacist/Authorized Designee: Executes randomization assignments, dispenses blinded product, and documents code breakages.
Data Manager: Manages randomization codes and verifies blinding integrity.
Sponsor/CRO: Provides randomization schemes, ensures systems are validated, and oversees blinding compliance.
Quality Assurance Officer: Reviews randomization and unblinding records during audits and inspections.

Accountability

The PI is accountable for maintaining randomization and blinding integrity. The sponsor is accountable for providing validated randomization systems and unblinding procedures.

Procedure

1. Randomization Process
Use validated IVRS/IWRS or manual sealed envelope systems for randomization.
Assign subject IDs sequentially, linked with treatment allocation.
Document allocations in Randomization Log (Annexure-1).

2. Blinding
Ensure blinding for double-blind trials by using identical packaging and labeling.
Limit access to randomization codes to authorized staff only.
File blinding documentation in ISF and TMF.

3. Emergency Unblinding
Unblinding is permitted only in medical emergencies when knowledge of treatment is essential for subject safety.
Document reason, authorization, and outcome in Unblinding Record (Annexure-2).
Notify sponsor and EC/IRB within 24 hours of unblinding.

4. Monitoring and Auditing
Sponsor monitors verify randomization compliance during site visits.
QA audits review logs for discrepancies and corrective actions.

5. Archiving
Archive randomization and blinding/unblinding records for at least 5 years post-trial or per local laws.